10X Genomics, Inc. Stock Price, News & Analysis

10x Genomics (TXG) has announced preliminary, unaudited results for Q4 and full year 2024. The company reported Q4 2024 revenue of ~$165.0 million, showing 9% sequential growth but a 10% year-over-year decrease. Full-year 2024 revenue reached ~$610.8 million, representing a 1% decrease from 2023.

Q4 breakdown shows Instruments revenue at $24.4 million (28% sequential growth, -37% YoY), Consumables revenue at $133.5 million (6% sequential growth, -5% YoY), and Services revenue at $7.1 million (12% sequential growth, +35% YoY). The company's cumulative instrument installations exceeded 7,000 units, including over 5,800 Chromium, 800 Visium, and 400 Xenium instruments. Cash position stood at approximately $393 million as of December 31, 2024.

10x Genomics (Nasdaq: TXG), a pioneer in single cell and spatial biology, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team is scheduled to present on Monday, January 13, at 7:30 a.m. Pacific Time.

The presentation will take the format of a fireside chat and will be accessible via live webcast through the 'Investors' section of 10x Genomics' website. For those unable to attend live, the webcast recording will remain available for replay for a minimum of 30 days following the event.

Bruker (BRKR) faces a permanent injunction in Delaware's U.S. District Court regarding its GeoMx products, following a patent infringement lawsuit by 10x Genomics. The Court will enter the injunction in January 2025, prohibiting Bruker from making, selling, or offering GeoMx Digital Spatial Profiler products in the United States.

The Court affirmed the $31 million damages from the November 2023 jury verdict, plus supplemental damages and interest. Notably, existing GeoMx users who installed instruments before November 18, 2023, can continue purchasing reagents for ongoing research. The jury found that the GeoMx products willfully infringed seven patents licensed to 10x Genomics by Prognosys.

10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, announced its management team will participate in a fireside chat at the Wolfe Research 2024 Healthcare Conference.

The event will take place on Tuesday, November 19, at 1:00 p.m. Eastern Time. Interested parties can access a live webcast of the chat on the Investors section of the company's website. The webcast will be archived and available for replay for at least 45 days after the event.

French TechBio startup Cure51 has selected 10x Genomics' Visium HD technology for analyzing tumor samples from exceptional cancer survivors. The initiative aims to study over 1,000 tumor samples across 40 countries in collaboration with more than 50 medical institutions over the next 18 months. Cure51 will use Visium HD's single cell-scale resolution capabilities to build the first proprietary multi-omics database of exceptional cancer survivors, focusing on understanding survival mechanisms for new therapeutic approaches. The company recently raised €15 million in Seed funding from Sofinnova, LifeX and Hitachi Ventures.

10x Genomics (TXG) reported Q3 2024 financial results with revenue of $151.7 million, representing a 1% decrease from the previous year. The company faced challenges due to sales restructuring disruption and cautious customer spending. Gross margin improved to 70% from 62% year-over-year, while operating loss decreased to $41.5 million from $94.8 million. Net loss was $35.8 million. The company launched several new products including GEM-X Flex and Chromium Xo. Due to persistent market challenges, 10x Genomics revised its full-year 2024 revenue guidance to $595-605 million, down from previous $640-660 million range.

10x Genomics has launched two new Chromium products to make single cell analysis more accessible and affordable. The GEM-X Flex and GEM-X Universal Multiplex offer improved performance, workflow, and cost-effectiveness. GEM-X Flex enables profiling of up to 2.5 million cells per run at a cost as low as $0.01 per cell, with compatibility for various sample types including FFPE samples. It requires as low as 25,000 cells per sample, a four-fold improvement in sample recovery.

The GEM-X Universal Multiplex allows on-chip multiplexing of four independent samples, up to 5,000 cells per sample, for approximately $560 per sample. This simplifies the workflow and reduces hands-on time. Both products aim to democratize single cell analysis by lowering costs per cell, sample, experiment, and project.

10x Genomics (Nasdaq: TXG) announced preliminary Q3 2024 results with revenue of approximately $151.7 million, a 1% decrease year-over-year. Consumables revenue grew 10% to $126.2 million, while instruments revenue declined 46% to $19.1 million. Services revenue increased 48% to $6.4 million.

Geographically, Americas revenue decreased 11%, while EMEA and APAC revenues increased 18% and 15%, respectively. The company ended the quarter with approximately $398 million in cash and cash equivalents.

CEO Serge Saxonov acknowledged that revenue fell short of expectations, citing disruptions from commercial process changes and cautious customer spending, particularly impacting instrument sales. The company will provide full year 2024 guidance during its earnings call on October 29, 2024.

At the Human Cell Atlas General Meeting in Milan, 10x Genomics (Nasdaq: TXG) announced plans to deliver 'single cell for a single cent'. The company aims to launch new products and configurations this quarter, enabling mega-scale single cell analysis at a cost as low as $0.01 per cell. These launches will allow for 2.5 million cells per run and 5 million cells per kit, making them the most cost-effective single cell products for high-throughput applications.

10x Genomics also plans to introduce cost-effective products for smaller-scale experiments, with single cell experiments starting at approximately $560 per sample. The company's strategy includes recent launches like the Chromium GEM-X Technology and Chromium Xo instrument, aimed at reducing customer costs and increasing accessibility to single cell analysis.